MiNK Therapeutics
INKT
19 hedge funds and large institutions have $461K invested in MiNK Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
12% more funds holding
Funds holding: 17 → 19 (+2)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.03% less ownership
Funds ownership: 1.59% → 1.55% (-0.03%)
15% less capital invested
Capital invested by funds: $544K → $461K (-$83.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TIM
Total Investment Management
Scottsdale,
Arizona
|
+$3.76K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.79K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$241 |
| 4 |
C
Covestor
London,
United Kingdom
|
+$203 |
| 5 |
KFI
Key Financial Inc
West Chester,
Pennsylvania
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.49K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.42K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$887 |
| 5 |
JP Morgan Chase
New York
|
-$135 |
INKT Hedge Fund Activity: Q2 2025 in Review
19 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2025, worth a combined $461K — down 15% from $544K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new INKT positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Total Investment Management, opening a new position worth an estimated $3.76K. The largest seller was BlackRock, cutting an estimated $10.2K.
- 19 institutional investors held MiNK Therapeutics (INKT) as of Q2 2025, up from 17 in Q1 2025.
- Funds reported $461K of MiNK Therapeutics stock for Q2 2025, down 15% quarter-over-quarter.
- 3 funds opened new MiNK Therapeutics positions in Q2 2025 and 1 closed out, a net change of +2 holders.
- The largest MiNK Therapeutics buyer in Q2 2025 was Total Investment Management, an estimated $3.76K added.
- The largest MiNK Therapeutics seller in Q2 2025 was BlackRock, an estimated $10.2K sold.
Based on aggregated 13F filings for Q2 2025.